Company Information
About Ixion
Products
Management expand tree
Financial Info
Shareholder Info expand tree
SEC/Finance Reports
Target Diseases
  Diabetes General Information
  Diabetes FAQ's
  Diabetes Economic Impact
  Diabetes Product Plan
  Diabetes Questions/Comments
  Kidney Stones
  Cystic Fibrosis
  Crohn's Disease
  Primary Hyperoxaluria
  Idiopathic Hyperoxaluria
  Vulvodynia
  Catheters & Stents
Questions/Comments

  Aspergillosis
  Companion (Animal)
Inside Ixion
          Scientific Articles
          Intellectual Property
Newsroom
          2003
          2002
          2001
Contact Us
   Online Form/Contact Info
   Directions & Map
Home 
Cystic Fibrosis   Links

 
      Cystic fibrosis is the most common autosomal recessive genetic disease within the Caucasian population. Specific DNA changes in the CFTR (cystic fibrosis transmembrane conductance regulator) gene results in an abnormal, or non-functioning, protein. This protein is associated with the normal secretion of chloride in the lungs, pancreas and sweat glands. The abnormal protein leads to less secretion of water, resulting in a very thick mucous which contributes to increased respiratory infections (especially Staphylococcus and Pseudomonas). Other organs which are affected by the abnormal CFTR protein include the liver, salivary glands and testes.
 
        Children with mild disease often survive to adolescence or young adulthood, when they may die of respiratory problems. Routine care involves therapeutic treatment with antibiotics (for example, Ceftazidine plus Amoxicillin). The gene which codes for the CFTR protein has already been cloned and its DNA sequence determined. For this reason, many of the DNA changes which cause an abnormal form of the protein have been identified. Cystic fibrosis has been one of the first diseases selected for possible curing using gene therapy. Clinical studies are already underway attempting to incorporate the normal gene into lung cells using a virus vector (or transport) system.
 
        At Ixion, we are interested in the fact that many cystic fibrosis patients have been observed to suffer hyperoxaluria, as well. The question is whether this condition is due to an inherent abnormal CFTR protein that interferes with oxalate excretion or whether the routine antibiotic therapy necessary to ward off infections eliminates Oxalobacter formigenes from the intestines. Preliminary studies have indicated cystic fibrosis patients with hyperoxaluria lack detectable O. formigenes.
 
 
 
Links:
Cystic Fibrosis 101
Health Care Information Services - Cystic Fibrosis
The International Cystic Fibrosis Association
Cystic Fibrosis Foundation
Cysticfibrosis.com